CN115151565A - 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法 - Google Patents

包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法 Download PDF

Info

Publication number
CN115151565A
CN115151565A CN202080090109.2A CN202080090109A CN115151565A CN 115151565 A CN115151565 A CN 115151565A CN 202080090109 A CN202080090109 A CN 202080090109A CN 115151565 A CN115151565 A CN 115151565A
Authority
CN
China
Prior art keywords
antibody
cells
antibody fragment
ser
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080090109.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·恩德尔
R·博克斯哈默
D·普雷切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of CN115151565A publication Critical patent/CN115151565A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080090109.2A 2019-10-31 2020-10-30 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法 Pending CN115151565A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206479 2019-10-31
EP19206479.8 2019-10-31
PCT/EP2020/080494 WO2021084063A1 (en) 2019-10-31 2020-10-30 Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells

Publications (1)

Publication Number Publication Date
CN115151565A true CN115151565A (zh) 2022-10-04

Family

ID=68424789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090109.2A Pending CN115151565A (zh) 2019-10-31 2020-10-30 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法

Country Status (23)

Country Link
US (1) US20210130461A1 (cg-RX-API-DMAC7.html)
EP (2) EP4706673A3 (cg-RX-API-DMAC7.html)
JP (2) JP7688025B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220116154A (cg-RX-API-DMAC7.html)
CN (1) CN115151565A (cg-RX-API-DMAC7.html)
AU (1) AU2020372646A1 (cg-RX-API-DMAC7.html)
DK (1) DK4051710T3 (cg-RX-API-DMAC7.html)
ES (1) ES3062643T3 (cg-RX-API-DMAC7.html)
FI (1) FI4051710T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251630T1 (cg-RX-API-DMAC7.html)
IL (1) IL292213A (cg-RX-API-DMAC7.html)
LT (1) LT4051710T (cg-RX-API-DMAC7.html)
MA (1) MA69251B1 (cg-RX-API-DMAC7.html)
MD (1) MD4051710T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005033A (cg-RX-API-DMAC7.html)
PH (1) PH12022551009A1 (cg-RX-API-DMAC7.html)
PL (1) PL4051710T3 (cg-RX-API-DMAC7.html)
PT (1) PT4051710T (cg-RX-API-DMAC7.html)
RS (1) RS67602B1 (cg-RX-API-DMAC7.html)
SI (1) SI4051710T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600082T1 (cg-RX-API-DMAC7.html)
TW (2) TWI922280B (cg-RX-API-DMAC7.html)
WO (1) WO2021084063A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR102617497B1 (ko) 2022-09-15 2023-12-27 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794231A (zh) * 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病(cll)的治疗
CN107660151A (zh) * 2015-05-26 2018-02-02 莫佛塞斯公司 抗‑cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
CN110267678A (zh) * 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2710123B1 (en) 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
CN118421557A (zh) 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) * 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794231A (zh) * 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病(cll)的治疗
CN107660151A (zh) * 2015-05-26 2018-02-02 莫佛塞斯公司 抗‑cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
CN110267678A (zh) * 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIROTAKE TOKUYAMA ET AL.: ""Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab"", 《INT.J.CANCER》, vol. 122, 31 December 2008 (2008-12-31), pages 2526 - 2534, XP071285149, DOI: 10.1002/ijc.23365 *
URSULA JÖRDIS EVA SEIDEL ET AL.: ""γδT cell-mediated antibody-dependent cellular cytotoxicity with CD19 antibodies assessed by an impedance-based label-free real-time cytotoxicity assay"", 《FRONTIERS IN IMMUNOLOGY》, vol. 5, 2 December 2014 (2014-12-02), pages 1 - 12, XP055591534, DOI: 10.3389/fimmu.2014.00618 *

Also Published As

Publication number Publication date
MA69251B1 (fr) 2025-12-31
TW202547555A (zh) 2025-12-16
WO2021084063A1 (en) 2021-05-06
DK4051710T3 (da) 2025-12-15
AU2020372646A1 (en) 2022-05-12
PH12022551009A1 (en) 2023-03-20
SI4051710T1 (sl) 2026-01-30
KR20220116154A (ko) 2022-08-22
ES3062643T3 (en) 2026-04-13
TWI883067B (zh) 2025-05-11
IL292213A (en) 2022-06-01
JP7688025B2 (ja) 2025-06-03
EP4706673A3 (en) 2026-05-20
EP4051710B1 (en) 2025-11-26
LT4051710T (lt) 2026-03-10
CA3158984A1 (en) 2021-05-06
TWI922280B (zh) 2026-04-11
US20210130461A1 (en) 2021-05-06
MX2022005033A (es) 2022-09-09
RS67602B1 (sr) 2026-01-30
SMT202600082T1 (it) 2026-03-09
JP2022554324A (ja) 2022-12-28
PL4051710T3 (pl) 2026-04-20
JP2025134705A (ja) 2025-09-17
HRP20251630T1 (hr) 2026-02-13
TW202131949A (zh) 2021-09-01
PT4051710T (pt) 2026-02-09
EP4051710A1 (en) 2022-09-07
EP4706673A2 (en) 2026-03-11
MD4051710T2 (ro) 2026-04-30
FI4051710T3 (fi) 2026-01-12

Similar Documents

Publication Publication Date Title
JP7728822B2 (ja) キメラ抗原受容体及びt細胞受容体並びに使用方法
JP7688025B2 (ja) 抗cd19抗体及びガンマデルタt細胞を含む抗腫瘍併用療法
CN102753195A (zh) 用于增强抗肿瘤抗体疗法的方法
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
CN114641312A (zh) 抗cd19疗法与来那度胺组合用于治疗白血病或淋巴瘤
CN113906049A (zh) 用于共施用针对c-kit和CD47的免疫治疗剂的方案
CA3158984C (en) Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EA050676B1 (ru) Противоопухолевая комбинированная терапия, включающая антитело к cd19 и гамма-дельта т-клетки
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
AU2020209425B2 (en) Antibody
HK40128442A (en) Chimeric antigen and t cell receptors and methods of use
HK40126667A (en) Chimeric antigen and t cell receptors and methods of use
KR20250060146A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
HK40061606B (en) Chimeric antigen receptors and car-t cells and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250409

Address after: Delaware, USA

Applicant after: INCYTE Corp.

Country or region after: U.S.A.

Address before: German Pla Neg

Applicant before: MORPHOSYS AG

Country or region before: Germany

TA01 Transfer of patent application right